Eli Lilly 30 avr. 2026 Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket - Barron's
Eli Lilly 30 avr. 2026 Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch - BioPharma Dive
Eli Lilly 30 avr. 2026 Eli Lilly: Stellar Q1 Earnings Put Pharma In Class Of Its Own, It's Ok To Buy Today (LLY) - Seeking Alpha
Eli Lilly 30 avr. 2026 Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's - Fierce Pharma
Eli Lilly 28 avr. 2026 Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace
Eli Lilly 28 avr. 2026 Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing - Fierce Biotech
Eli Lilly 28 avr. 2026 Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine - Business Wire
Eli Lilly 27 avr. 2026 Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs - CNBC
Eli Lilly 27 avr. 2026 Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet - Reuters
Eli Lilly 27 avr. 2026 Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax - Fierce Biotech
Eli Lilly 24 avr. 2026 A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B - statnews.com
Eli Lilly 20 avr. 2026 Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation? - The Motley Fool
Eli Lilly 20 avr. 2026 Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics - Pharmaceutical Executive